Honz Pharmaceutical Co., Ltd. Class A

Honz Pharmaceutical Co., Ltd. Class A

SSZSE:300086
4.53
CNY
-0.14
(-3.00%)
-0.47EPS
2.44BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.69
0.91
0.91
1.05
1.48
1.96
2.24
2.05
1.86
1.19
1.53
1.04
1.02
0.74
Basic EPS, GAAP
0.03
0.14
0.15
0.1
0.12
0.03
-0.06
0.02
0.02
-0.42
-0.03
-0.48
-0.51
-0.46
Free Cash Flow per Basic Share
0.05
0.1
0.02
0.11
-0.3
-0.3
-0.19
-0.7
-0.46
-0.04
-0.15
-0.05
0.06
- -
Dividend per Share
0.14
0.06
0.07
0.01
0.02
0.02
0.18
0.05
0.09
0.06
0.05
0.04
0.04
0.03
Book Value per Share
3.84
3.83
3.94
4
4.11
3.41
3.33
3.34
3.34
2.92
2.93
2.45
1.98
1.81
Tangible Book Value per Share
3.24
3.21
3.2
3.29
3.43
2.08
2.19
2.22
2.77
2.43
2.43
2
1.75
1.59
Basic Weighted Avg Shares
450
450
450
450
450
450
450
449
450
450
450
451
455
455
Sales/Revenue/Turnover
309
409
410
471
668
883
1,008
922
837
536
689
470
466
336
Operating Margin (%)
1.37
11.48
13.31
7.59
7.96
5.23
1.88
9.2
1.82
-22.66
4.54
-27.53
-34.34
-32.34
Depreciation Expense
41
46
47
43
47
56
62
50
45
50
77
64
68
- -
Net Income, GAAP
15
62
68
46
56
13
-26
9
11
-188
-14
-215
-230
-209
Effective Tax Rate (%)
50.71
21.93
22.61
20.88
15.84
38.44
- -
30.51
48.06
- -
- -
- -
- -
- -
Profit Margin (%)
4.8
15.2
16.64
9.79
8.31
1.51
-2.62
1.01
1.31
-35.01
-1.98
-45.89
-49.37
-62.37
Working Capital
1,160
1,186
1,199
1,196
1,071
213
36
118
235
166
196
-78
-279
-347
LT Debt
- -
- -
- -
- -
20
13
29
337
344
343
325
229
199
172
Total Equity
1,810
1,805
1,853
1,873
1,921
1,645
1,602
1,602
1,554
1,356
1,353
1,141
921
844
Return on Invested Capital (%)
0.67
2.97
3.33
1.93
2.79
1.06
- -
1.96
0.5
- -
- -
- -
- -
- -
Return on Capital (%)
0.03
2.26
3.76
2.91
3
0.6
- -
0.56
0.96
- -
- -
- -
- -
- -
Return on Common Equity (%)
0.84
3.6
3.9
2.58
3.04
0.79
-1.74
0.62
0.73
-13.3
-1.03
-17.7
-22.84
-22.35

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
235
255
276
LT Borrowings
182
154
154
LT Finance Leases
18
18
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
455
455
455
Market Capitalization
3,746
2,685
2,444

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
269
258
220
Cash, Cash Equivalents & STI
17
16
6
Accounts Receivable, Net
41
30
25
Inventories
160
169
150
Total Current Liabilities
542
567
567
Payables & Accruals
- -
- -
- -
ST Debt
235
255
276
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-10.18%
-19.26%
Free Cash Flow
10.47%
-21.92%
-238.38%
Net Income, GAAP
-91.71%
-79.18%
6.82%
Sales/Revenue/Turnover
4.54%
-9.83%
-0.72%
Total Cash Common Dividend
67.7%
0.36%
-17.02%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
105
115
144
106
470
2025
112
120
- -
140
466
2026
97
48
51
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.1
-0.12
-0.05
-0.2
-0.48
2025
-0.02
-0.1
- -
-0.29
-0.51
2026
-0.03
-0.05
-0.09
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.04
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Jiang Tao Hong
Full Time Employees
540
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 6, Yaogu Third Road Guangzhou HA China 570311
IPO Date
May 26, 2010
Business
Honz Pharmaceutical Co., Ltd. (300086.SZ) engages in the research, development, manufacturing, and sales of pediatric medicines and related healthcare products primarily in China. Founded in 1994 and headquartered in Haikou, Hainan with major operations in Guangzhou, Guangdong, the company maintains five highly automated manufacturing bases across Hainan, Beijing, Hebei, Liaoning, and Guangdong, alongside a new EU GMP-standard facility under construction in Zhongshan, Guangdong. Its core products encompass children's medicines including respiratory treatments such as Ruizhiqing and Kangzhisong, digestive medicines like Kangzhitai, anti-allergic drugs, antibiotics, nutritional supplements, antibacterial and antiviral drugs, antipyretic and analgesic drugs such as Jinlishuang, adult medicines, gynecological drugs, maternal and child health products, and medical devices including masks and protective equipment; the company targets children's health markets with a focus on national branding under the Honz label. Honz Pharmaceutical recently completed the acquisition of Zhongshan Care for Baby Daily Products Co., Ltd. from Hainan Hongshi Investment Co., Ltd. in August 2024 to bolster its maternal and child portfolio, while its controlling shareholder plans to increase its stake by up to 2% through a CNY100 million investment; the firm also earned recognitions such as the 2023 Hainan Top 40 Manufacturing Enterprises and Excellent ESG Case awards, alongside ongoing implementation of its Children's Health Global Strategy.